Akero Therapeutics is a clinical-stage company developing transformational therapies for people with metabolic dysfunction-associated steatohepatitis (MASH). Akero Therapeutics Announces Week 96 Results from Phase 2b SYMMETRY Study.

Our multi-modal investigational drug, efruxifermin (EFX), is designed to treat MASH holistically. EFX has been engineered to mimic the biological activity of fibroblast growth factor 21 (FGF21), which regulates multiple metabolic pathways and cellular processes.

Akero is a clinical-stage company founded to develop transformational treatments for patients with serious metabolic diseases marked by high unmet medical need. We began with an engineered protein called efruxifermin (EFX), which we licensed from Amgen and are developing for treatment of metabolic dysfunction-associated steatohepatitis (MASH).

6 days ago · Armstrong 2025年1月27日， Akero Therapeutics 公布FGF21融合蛋白新药Efruxifermin（EFX）在2b期临床中显著逆转MASH四期代偿性肝硬化。此前的MASH临床进展集中在F2-F3期的疗效突破，而F4肝硬化无疑是最后一个也是最大的挑战。此次Efruxifermin的突破性2b期临床数据， Akero Therapeut...

Jan 13, 2025 · Efruxifermin (EFX), Akero’s lead product candidate for MASH, is a differentiated Fc-FGF21 fusion protein that has been engineered to mimic the balanced biological activity profile of native FGF21, an endogenous hormone that alleviates cellular stress and regulates metabolism throughout the body.

9月13日，Akero Therapeutics宣布旗下药物Efruxifermin（EFX，曾用名AKR-001）在IIb期HARMONY研究中，可改善肝硬化前期非酒精性 脂肪性肝炎 （NASH）患者的 肝纤维化 并防止疾病恶化，Efruxifermin 28mg和50mg剂量组均达到了改善肝脏纤维化的主要终点以及多个次要终点。

Sep 13, 2022 · Efruxifermin (EFX), formerly known as AKR-001, is Akero’s lead product candidate for NASH, currently being evaluated in the ongoing Phase 2b HARMONY study. EFX is designed to reduce liver fat and inflammation, reverse fibrosis, increase insulin sensitivity and …

Jan 24, 2025 · Efruxifermin (EFX), Akero’s lead product candidate for MASH, is currently being evaluated in three ongoing Phase 3 studies. In multiple Phase 2 studies, EFX has been observed to reverse fibrosis (including compensated cirrhosis), resolve MASH, reduce non-invasive markers of fibrosis and liver injury, and improve insulin sensitivity and ...

5 days ago · In essence, it is expected that Akero Therapeutics is going to release 52-week data from its phase 3 SYNCHRONY Real-World study using EFX to treat F1-F3 MASH patients, in the 1st half of 2026.

Mar 5, 2024 · 3月4日，Akero Therapeutics公布了HARMONY研究96周初步积极结果，该项IIb期研究评估了其主要候选产品efruxifermin (EFX) 对肝硬化前代谢功能障碍相关脂肪性肝炎（MASH，之前被称为NASH），纤维化2期或3期（F2-F3）患者的有效性和安全性。